You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

TOPAMAX SPRINKLE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Topamax Sprinkle, and when can generic versions of Topamax Sprinkle launch?

Topamax Sprinkle is a drug marketed by Janssen Pharms and is included in one NDA.

The generic ingredient in TOPAMAX SPRINKLE is topiramate. There are twenty-six drug master file entries for this compound. Fifty-four suppliers are listed for this compound. Additional details are available on the topiramate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Topamax Sprinkle

A generic version of TOPAMAX SPRINKLE was approved as topiramate by ACCORD HLTHCARE on March 27th, 2009.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for TOPAMAX SPRINKLE?
  • What are the global sales for TOPAMAX SPRINKLE?
  • What is Average Wholesale Price for TOPAMAX SPRINKLE?
Drug patent expirations by year for TOPAMAX SPRINKLE
Drug Prices for TOPAMAX SPRINKLE

See drug prices for TOPAMAX SPRINKLE

Recent Clinical Trials for TOPAMAX SPRINKLE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Mylan PharmaceuticalsPhase 1
Teva Pharmaceuticals USAPhase 1

See all TOPAMAX SPRINKLE clinical trials

Paragraph IV (Patent) Challenges for TOPAMAX SPRINKLE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
TOPAMAX SPRINKLE Capsules topiramate 15 mg and 25 mg 020844 1 2005-09-07

US Patents and Regulatory Information for TOPAMAX SPRINKLE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Janssen Pharms TOPAMAX SPRINKLE topiramate CAPSULE;ORAL 020844-003 Oct 26, 1998 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for TOPAMAX SPRINKLE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Janssen Pharms TOPAMAX SPRINKLE topiramate CAPSULE;ORAL 020844-003 Oct 26, 1998 ⤷  Sign Up ⤷  Sign Up
Janssen Pharms TOPAMAX SPRINKLE topiramate CAPSULE;ORAL 020844-003 Oct 26, 1998 ⤷  Sign Up ⤷  Sign Up
Janssen Pharms TOPAMAX SPRINKLE topiramate CAPSULE;ORAL 020844-003 Oct 26, 1998 ⤷  Sign Up ⤷  Sign Up
Janssen Pharms TOPAMAX SPRINKLE topiramate CAPSULE;ORAL 020844-003 Oct 26, 1998 ⤷  Sign Up ⤷  Sign Up
Janssen Pharms TOPAMAX SPRINKLE topiramate CAPSULE;ORAL 020844-003 Oct 26, 1998 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for TOPAMAX SPRINKLE

See the table below for patents covering TOPAMAX SPRINKLE around the world.

Country Patent Number Title Estimated Expiration
Japan 2003530295 ⤷  Sign Up
South Korea 920001775 ⤷  Sign Up
Norway 170280 ⤷  Sign Up
New Zealand 209494 SULPHAMATES,INTERMEDIATES AND PHARMACEUTICAL COMPOSITIONS ⤷  Sign Up
Argentina 048456 COMPOSICION FARMACEUTICA DE TOPIRAMATO ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for TOPAMAX SPRINKLE

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0138441 97C0097 Belgium ⤷  Sign Up PRODUCT NAME: TOPIRAMAAT; NAT. REGISTRATION NO/DATE: 1028 IS 71 F 3 19970616; FIRST REGISTRATION: GB PL/0242/0301 19950718
2317997 2190050-1 Sweden ⤷  Sign Up PRODUCT NAME: PHENTERMINE AND TOPIRAMATE; NAT. REG. NO/DATE: 59574-59577 20210617; FIRST REG.: IS IS/1/21/018/01-04 20210212
0138441 SPC/GB95/028 United Kingdom ⤷  Sign Up PRODUCT NAME: TOPIRAMATE; REGISTERED: UK 0242/0301 19950718
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.